Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | AGPAT2 | O15120 | 4/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4570096 | 0.95 | HSD11B1 (0.37) | S1PR1AGPAT2SERPINE1CYP2C9TAAR1 | |
| SCHEMBL17082129 | 0.95 | HSD11B1 (0.37) | S1PR1AGPAT2SERPINE1CYP2C9TAAR1 | |
| SCHEMBL4570037 | 0.91 | KMT2A (0.35) | CYP2C9MAPT | |
| SCHEMBL4570136 | 0.90 | TAAR1 (0.39) | ALKS1PR1CYP2C9TAAR1EML4 | |
| SCHEMBL17082166 | 0.90 | TAAR1 (0.39) | ALKS1PR1CYP2C9TAAR1EML4 | |
| SCHEMBL4570209 | 0.89 | ALDH1A1 (0.38) | AGPAT2CYP2C9MAPT | |
| SCHEMBL17081992 | 0.89 | ALDH1A1 (0.38) | AGPAT2CYP2C9MAPT | |
| SCHEMBL4570138 | 0.89 | TP53 (0.40) | ALKS1PR1CYP2C9TAAR1EML4 | |
| SCHEMBL17082167 | 0.89 | TP53 (0.40) | ALKS1PR1CYP2C9TAAR1EML4 | |
| SCHEMBL4570137 | 0.88 | S1PR1 (0.41) | ALKS1PR1CYP2C9TAAR1EML4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | ALK 3964/4885S1PR1 1221/4885AGPAT2 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.